ANI Pharmaceuticals Inc. (NASDAQ:ANIP)’s share price traded down 2.5% during trading on Friday . The company traded as low as $55.77 and last traded at $56.66, with a volume of 126,339 shares traded. The stock had previously closed at $58.12.

A number of equities analysts recently commented on the company. Guggenheim reiterated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of ANI Pharmaceuticals in a research note on Saturday, May 7th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $55.00 price target for the company in a research note on Tuesday, April 26th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of ANI Pharmaceuticals in a research note on Tuesday, May 3rd. Standpoint Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 24th. Finally, Citigroup Inc. downgraded ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 target price for the company. in a research note on Friday. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $55.88.

The company has a market capitalization of $649.47 million and a price-to-earnings ratio of 53.11. The company’s 50-day moving average price is $54.02 and its 200 day moving average price is $42.21.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, May 5th. The specialty pharmaceutical company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.12. During the same period last year, the business posted $0.57 EPS. The business earned $20.60 million during the quarter, compared to the consensus estimate of $21.03 million. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. On average, equities research analysts forecast that ANI Pharmaceuticals Inc. will post $3.67 EPS for the current fiscal year.

A number of hedge funds and institutional investors have added to or reduced their stakes in ANIP. Deere & Co. acquired a new position in ANI Pharmaceuticals during the fourth quarter worth $1,961,000. Principal Financial Group Inc. increased its position in ANI Pharmaceuticals by 4.9% in the fourth quarter. Principal Financial Group Inc. now owns 49,979 shares of the specialty pharmaceutical company’s stock worth $2,255,000 after buying an additional 2,355 shares during the period. Mutual of America Capital Management LLC increased its position in ANI Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 30,178 shares of the specialty pharmaceutical company’s stock worth $1,362,000 after buying an additional 178 shares during the period. Finally, GSA Capital Partners LLP increased its position in ANI Pharmaceuticals by 10.8% in the fourth quarter. GSA Capital Partners LLP now owns 55,447 shares of the specialty pharmaceutical company’s stock worth $2,502,000 after buying an additional 5,420 shares during the period.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.